Wells Fargo Downgrades Kymera Therapeutics to Equal-Weight, Announces $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has downgraded Kymera Therapeutics (KYMR) from Overweight to Equal-Weight and set a price target of $26.
December 19, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kymera Therapeutics was downgraded by Wells Fargo from Overweight to Equal-Weight with a price target of $26.
Downgrades by analysts can lead to a negative perception among investors and potentially cause a short-term decline in the stock price. The new price target of $26 may also set investor expectations on the stock's value.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100